Antidepressant agents for the treatment of chronic pain and depression

Pharmacotherapy

Volumn 27, Issue 11, 2007, Pages 1571-1587

  Jann, Michael W ^a   Slade, Julian H ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

Antidepressants; Chronic pain; Depression; Duloxetine; Neuropathy; Norepinephrine; Paroxetine; Serotonin; TCA; Tricyclic antidepressants; Venlafaxine

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZATROPINE; DESIPRAMINE; DULOXETINE; FLUOXETINE; GABAPENTIN; HEMOGLOBIN A1C; IBUPROFEN; IMIPRAMINE; MORPHINE; NEUROTRANSMITTER; NORADRENALIN; OXALIPLATIN; PARACETAMOL; PAROXETINE; PLACEBO; PREGABALIN; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; CHRONIC PAIN; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ECG ABNORMALITY; FATIGUE; HEADACHE; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERESTHESIA; HYPERGLYCEMIA; NAUSEA; NEUROMODULATION; NEUROPATHY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PHYSICAL DISEASE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOMNOLENCE; SWEATING; SYMPTOMATOLOGY; VAGUS NERVE STIMULATION; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DEPRESSION; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; HUMANS; PAIN;

EID: 35848958367     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.11.1571     Document Type: Review

References (47)

1. Lepine JP, Briley M. The epidemiology of pain and depression. Hum Psychopharmacol Clin Exp 2004;19:S3-7.
2. Banks SM, Kerns RD. Explaining the high rates of depression in chronic pain: a diathesis-stress framework. Psychol Bull 1996;119:95-110.
3. Burt VK. Plotting the course to remission: the search for better outcomes in the treatment of depression. J Clin Psychiatry 2004;65(suppl 12):20-5.
4. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001;413:203-10.
5. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000;288:1765-8.
6. Costigan M, Woolf CJ. Pain: molecular mechanisms. J Pain 2000;1(suppl 1):35-44.
7. Mannion RJ, Woolf CJ. Pain mechanisms and management: a cultural perspective. Clin J Pain 2000;16:S144-56.
8. Jensen TS, Gottrup H, Sindrup SH, Bach FW. The clinical picture of neuropathic pain. Eur J Pharmacol 2001;429:1-11.
9. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants: potential for greater efficacy or just hype? Prog Drug Res 2002;58:171-222.
10. Blier P, Abbott FV. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 2001;26:37-43.
11. Siever LJ, Davis KL. Overview: toward a dysregulation hypothesis of depression. Am J Psychiatry 1985;142:1017-31.
12. Stahl SM. The psychopharmacology of painful physical symptoms in depression. J Clin Psychiatry 2002;63:382-3.
13. Stahl SM, Briley M. Understanding pain in depression. Hum Psychopharmacol Clin Exp 2004;19:S9-13.
14. Kwiat GC, Basbaum AI. The origin of brainstem noradrenergic and serotonergic projections to the spinal cord dorsal horn in the rat. Somatosens Mot Res 1992;9:157-73.
15. Proudfit HK, Clark FM. The projections of locus coeruleus neurons to the spinal cord. In: Barnes CD, Pompeiano O, eds. Progress in brain research. New York: Elsevier Science Publications, 1991:123-41.
16. Clark FM, Proudfit HK. The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception. Brain Res 1993;616:200-10.
17. Clark FM, Proudfit HK. The projections of the noradrenergic neurons A7 catecholamine cell group to the spinal cord in the rat demonstrated by anterograde tracing combined with immunocheinistry Brain Res 1991;547:279-88.
18. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Ann Rev Neurosci 1984;7:309-38.
19. Mogil JS, Yu L, Basbaum AI. Pain genes? Natural variation and transgenic mutants. Ann Rev Neurosci 2000;23:777-811.
20. Magni G. The use of antidepressants in the treatment of chronic pain: a review of the current evidence. Drugs 1991;42:730-48.
21. Mochizucki D. Serotonin and noradrenaline reuptake Inhibitors in animal models of pain. Hum Psychopharmacol Clin Exp 2004;19:S15-19.
22. Mico JA, Ardid D, Berrocoso E, Eschalier A. Antidepressants and pain. Trends Pharmacol Sci 2006;27:348-54.
23. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors. Neuropsychopharmacology 2001;25:871-80.
24. Koch S, Hemrick-Lemke SK, Thompson LK, et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 2003;45:935-44.
25. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RMA. Efficacy of duloxetine, a potent and balanced Serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004;311:576-84.
26. Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonin and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 2005;312:726-32.
27. Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 2004;24:621-9.
28. Marchand F, Alloui A, Pelissier T, et al. Evidence for a hypertensive effect of venlafaxine in vincristine-induced neuropathy in rat. Brain Res 2003;980:117-20.
29. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-99.
30. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15.
31. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004;65:521-30.
32. Brannan SK, Mallinckrodt CH, Brown EB, Wholreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43-53.
33. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84.
34. Bradley RH, Barkin RL, Jerome J, et al. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003;10:318-23.
35. Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med 2004;19:813-18.
36. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400.
37. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-6.
38. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-18.
39. Raskin J, Pritchett YL, Bailey RK, et al. Duloxetine in the treatment of diabetic peripheral neuropathic pain - results from 3 clinical trials. Presented at the American academy of nurse practitioners, Fort Lauderdale, FL, June 14-17, 2005.
40. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56.
41. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004;110:697-706.
42. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus Imipramine in painful polyneuropathy. Neurology 2003;60:1284-9.
43. Durand JP, Alexandre J, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anti Cancer Drugs 2005;16:587-91.
44. Rush AJ, Marangell BM, Sackeim HA, et al. Vagus nerve stimulation for the treatment-resistant depression: a randomized controlled acute phase trial. Biol Psychiatr 2005;58:347-54.
45. George MS, Rush AJ, Marangell BM, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatr 2005;58:364-73.
46. Janig W, Khasar SG, Levine JD, Maio FJP. The role of vagal visceral afferents in the control of nociception. In: Mayer EA, Saper CB, eds. Progress in brain research. New York: Elsevier Science Publications, 2000:273-87.
47. Multon S, Schoenen J. Pain control by vagus nerve stimulation: from animal to man...and back. Acta Neurol Belg 2005;105:62-7.